ThermoGenesis (THMO) 10-K 21 Sep 16 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Sep. 16, 2016	Dec. 31, 2015
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	811,212
Trading Symbol	kool
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		9,790,500
Entity Public Float			$ 5,975
Document Type	10-K
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 5,835,000	$ 3,357,000
Accounts receivable, net of allowance for doubtful accounts of $49 ($46 at June 30, 2015)	3,169,000	5,133,000
Inventories, net of reserves of $1,437 ($874 at June 30, 2015)	3,593,000	4,598,000
Prepaid expenses and other current assets	246,000	163,000
Total current assets	12,843,000	13,251,000
Equipment at cost less accumulated depreciation	2,962,000	2,937,000
Goodwill	13,195,000	13,195,000
Intangible assets, net	20,821,000	21,295,000
Other assets	78,000	79,000
Total assets	49,899,000	50,757,000
Current liabilities:
Accounts payable	2,648,000	5,079,000
Accrued payroll and related expenses	449,000	705,000
Deferred revenue	783,000	635,000
Other current liabilities	1,662,000	1,527,000
Total current liabilities	5,542,000	7,946,000
Noncurrent deferred tax liability	7,641,000	7,641,000
Derivative obligations	670,000	0
Convertible debentures, net	2,489,000
Other noncurrent liabilities	1,284,000	268,000
Total liabilities	17,626,000	15,855,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding at June 30, 2016 and 2015
Common stock, $0.001 par value; 350,000,000 shares authorized; 3,010,687 issued and outstanding (2,027,386 at June 30, 2015)	3,000	2,000
Paid in capital in excess of par	188,569,000	172,579,000
Accumulated deficit	(156,262,000)	(137,674,000)
Accumulated other comprehensive loss	(37,000)	(5,000)
Total stockholders’ equity	32,273,000	34,902,000
Total liabilities and stockholders’ equity	$ 49,899,000	$ 50,757,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Accounts Receivable, Allowance for Doubtful Accounts	$ 49	$ 46
Inventories, reserves	$ 1,437	$ 874
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	3,010,687	2,027,386
Common stock, shares outstanding (in shares)	3,010,687	2,027,386

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Net revenues	$ 11,929	$ 16,042
Cost of revenues	9,185	11,293
Gross profit	2,744	4,749
Expenses:
Sales and marketing	2,148	2,974
Research and development	3,230	5,939
General and administrative	8,231	10,695
Total operating expenses	13,609	19,608
Loss from operations	(10,865)	(14,859)
Other income (expense):
Amortization of debt discount	(6,127)
Fair value change of derivative instruments	3,395
Interest expense	(1,864)	(14)
Registration rights liquidated damages	(1,100)
Loss on cashless exercise of warrants	(1,039)
Loss on extinguishment of debt	(795)
Loss on modification of Series A warrants	(149)
Other income and (expenses)	(44)	21
Total other income (expense)	(7,723)	7
Net loss	(18,588)	(14,852)
COMPREHENSIVE LOSS
Net loss	(18,588)	(14,852)
Foreign currency translation adjustments	(32)	(63)
Comprehensive loss	$ (18,620)	$ (14,915)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (7.57)	$ (7.36)
Weighted average common shares outstanding – Basic and diluted (in shares)	2,455,548	2,017,597

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Series B Warrant [Member]Common Stock [Member]	Series B Warrant [Member]Paid in Capital in Excess of Par [Member]	Series B Warrant [Member]	Common Stock [Member]	Paid in Capital in Excess of Par [Member]	Accumulated Deficit [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Jun. 30, 2014				2,012,326
Balance at Jun. 30, 2014				$ 2	$ 171,460	$ (122,822)	$ 58	$ 48,698
Issuance of common shares and compensation related to restricted common stock awards, net of stock surrenders (in shares)				12,801
Issuance of common shares and compensation related to restricted common stock awards, net of stock surrenders					414			414
Stock-based compensation expense					660			660
Common stock issued to directors in lieu of cash compensation (in shares)				2,259
Common stock issued to directors in lieu of cash compensation					45			45
Foreign currency translation							(63)	(63)
Net loss						(14,852)		(14,852)
Balance (in shares) at Jun. 30, 2015				2,027,386
Balance at Jun. 30, 2015				$ 2	172,579	(137,674)	(5)	34,902
Stock-based compensation expense					710			710
Common stock issued to directors in lieu of cash compensation (in shares)				4,720
Common stock issued to directors in lieu of cash compensation					24			24
Foreign currency translation							(32)	(32)
Net loss						(18,588)		(18,588)
Balance (in shares) at Jun. 30, 2016				3,010,687
Balance at Jun. 30, 2016				$ 3	188,569	$ (156,262)	$ (37)	32,273
Stock-based compensation expense, net of stock surrenders (in shares)				11,577
Discount due to beneficial conversion features					7,262			7,262
Discount due to warrants					4,434			4,434
Issuance of common shares and warrants in financing (in shares)				735,294
Issuance of common shares and warrants in financing				$ 1	$ 2,463			$ 2,464
Issuance of common shares for exercise of Series B warrants (in shares)	231,710
Issuance of common shares for exercise of Series B warrants		$ 1,097	$ 1,097

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (18,588,000)	$ (14,852,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,168,000	1,351,000
Stock-based compensation expense	742,000	1,247,000
Reserve for excess and slow-moving inventories	566,000	162,000
Amortization of Debt Discount (Premium)	6,127,000
Amortization of Debt Issuance Costs	800,000
Change in fair value of derivative obligation	(3,395,000)
Non-cash accrued interest	1,031,000
Loss on cashless exercise of warrants	1,039,000
Loss on extinguishment of debt	795,000
Loss on modification of Series A warrants	149,000
Impairment of intangible asset		117,000
Net changes in operating assets and liabilities:
Accounts receivable	1,956,000	(459,000)
Inventories, Net	375,000	254,000
Prepaid other assets	(86,000)	54,000
Accounts payable	(2,420,000)	1,410,000
Accrued payroll and related expenses	(256,000)	105,000
Deferred revenue	148,000	(3,000)
Other current liabilities	160,000	(76,000)
Other noncurrent liabilities	64,000	41,000
Net cash (used in) operating activities	(9,625,000)	(10,649,000)
Cash flows from investing activities:
Capital expenditures	(710,000)	(587,000)
Net cash (used in) investing activities	(710,000)	(587,000)
Cash flows from financing activities:
Gross proceeds from convertible debentures	18,000,000
Payment of financing cost – convertible debentures	(961,000)
Repayment of convertible debentures	(6,444,000)
Payment to extinguish derivative obligations	(159,000)
Payments on capital lease obligations	(67,000)	(60,000)
Proceeds from issuance of common stock, net	2,463,000
Repurchase of common stock	(8,000)	(129,000)
Net cash (used in) provided by financing activities	12,824,000	(189,000)
Effects of foreign currency rate changes on cash and cash equivalents	(11,000)	(29,000)
Net (decrease)increase in cash and cash equivalents	2,478,000	(11,454,000)
Cash and cash equivalents at beginning of year	3,357,000	14,811,000
Cash and cash equivalents at end of year	5,835,000	3,357,000
Supplemental non-cash financing and investing information:
Derivative obligation related to issuance of warrants	4,282,000
Reclassification of derivative liability to equity	58,000
Transfer of inventories to equipment	18,000	539,000
Equipment acquired by capital lease		208,000
Retirement of equipment	$ 1,109,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (Cesca, the Company) develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. Cesca is a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Reverse Stock Split On March 4, 2016, the Company effected a one (1) for twenty (20) reverse split of its issued and outstanding common stock. There were no changes to its authorized number of shares of common stock of 350,000,000. All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split. No fractional shares were issued; fractional shares of common stock were rounded up to the nearest whole share. Liquidity On August 3, 2016, the Company sold 600,000 shares of common stock at a price of $4.10 per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the estimated offering expenses borne by the Company are expected to be approximately $2.2 million. On August 22, 2016, the Company elected to convert all outstanding principal and interest accrued and otherwise payable under the secured convertible debentures. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures and all security interest and liens were terminated. At June 30, 2016, the Company had cash and cash equivalents of $5,835 and working capital of $7,301. The Company has incurred recurring operating losses and as of June 30, 2016 had an accumulated deficit of $156,262. The Company has primarily financed operations to date through the sale of equity securities and the sale of certain non-core assets. In February 2016, the Company completed a financing transaction (“the Financing Transaction”) for gross proceeds of $15 million. Half, or $7.5 million, of the proceeds were used to pay the investors in the August 2015 financing to repay the convertible debentures, liquidated damages and interest. Net proceeds after the repayment and issue costs were $7.3 million. Based upon the Company’s cash balance, the August 2016 Financing, historical trends, expected outflows and projections for revenues, management believes it will have sufficient cash to provide for its projected needs to maintain operations and working capital requirements for at least the next 12 months from the date of filing this annual report. The Company will need additional funding to support its phase III Critical Limb Ischemia (CLIRST III) trial. As such, management has been exploring additional funding sources including strategic partner relationships. The Company cannot assure that such funding will be available on a timely basis, in needed quantities, or on favorable terms, if at all. Principles of Consolidation The consolidated financial statements include the accounts of Cesca Therapeutics Inc., and the Company’s wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation, warranty costs, assumptions made in valuing equity instruments issued for services or acquisitions, deferred income taxes and related valuation allowance and the fair values of intangibles and goodwill. Actual results could materially differ from the estimates and assumptions used in the preparation of the Company’s consolidated financial statements. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying consolidated financial statements through the date of issuance. Revenue Recognition Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet. The Company’s sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors. Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting. Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years. All other service revenue is recognized at the time the service is completed. Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash is maintained in checking accounts, money market funds and certificates of deposits with reputable financial institutions that may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation. The Company has cash and cash equivalents of $104 and $247 at June 30, 2016 and 2015, respectively in India. The Company has not experienced any realized losses on the Company’s deposits of cash and cash equivalents. Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not necessarily agree with changes in the corresponding balances on the consolidated balance sheet. Equity accounts other than retained earnings are translated at the historic exchange rate on the date of investment. A translation loss of $32 and $63 was recorded for the years ended June 30, 2016 and 2015, respectively, as a component of other comprehensive income. Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not considered to have an indefinite useful life are amortized over their useful lives, which generally range from three to ten years. Clinical protocols are not expected to provide economic benefit until they are introduced to the marketplace or licensed to an independent entity. Each period the Company evaluates the estimated remaining useful lives of purchased intangible assets and whether events or changes in circumstances warrant a revision to the remaining periods of amortization. For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. According to ASC 350, Intangibles-Goodwill and Other The Company performed a quantitative assessment as of April 1, 2016 and computed a fair value based on a combination of the income approach and market approach, which determined that the fair value exceeded the carrying amount. Accordingly, there was no impairment of goodwill or the indefinite-lived intangible assets. For the definite-lived intangible assets, there were no facts or changes in circumstances that indicated the carrying value may not be recoverable. As such, no assessment was required and there was no impairment of these assets. Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures set or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs. Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third parties that will be settled in cash. The carrying value of the Company’s receivables, net of the allowance for doubtful accounts, represents their estimated net realizable value. The Company estimates the allowance for doubtful accounts based on historical collection trends, age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that a specific receivable balance may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. A customer’s receivable balance is considered past-due based on its contractual terms. Past-due receivable balances are written-off when the Company’s internal collection efforts have been unsuccessful in collecting the amount due. Inventories Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out basis. The Company writes-down to its estimated net realizable value when conditions indicate that the selling price could be less than cost due to physical deterioration, obsolescence, changes in price levels, or other causes, which it includes as a component of cost of revenues. Additionally, the Company provides valuation allowances for excess and slow-moving inventory on hand that are not expected to be sold to reduce the carrying amount of slow-moving inventory to its estimated net realizable value. The valuation allowances are based upon estimates about future demand from its customers and distributors and market conditions. Because some of the Company’s products are highly dependent on government and third-party funding, current customer use and validation, and completion of regulatory and field trials, there is a risk that the Company will forecast incorrectly and purchase or produce excess inventories. As a result, actual demand may differ from forecasts and the Company may be required to record additional inventory valuation allowances that could adversely impact its gross margins. Conversely, favorable changes in demand could result in higher gross margins when those products are sold. Equipment Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight line method over their estimated useful lives or the remaining lease period, whichever is shorter. Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure. Debt Issue Costs The Company amortizes debt issue costs to interest expense over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Debt Discount The Company amortizes debt discount over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Such amortized cost is included with the other income (expense) in the accompanying consolidated statements of operations. Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may also issue freestanding warrants. If freestanding warrants are issued and accounted for as derivative instrument liabilities (rather than as equity), the proceeds are first allocated to the fair value of those instruments. The remaining proceeds, if any, are then allocated to the convertible instrument, usually resulting in that instrument being recorded at a discount from its face amount. Derivative financial instruments are initially measured at their fair value using a Binomial Lattice Valuation Model and then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. Stock-Based Compensation The Company has two stock-based compensation plans, which are described more fully in Note 8. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not include a discount for post-vesting restrictions, as we have not issued awards with such restrictions. Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that corresponded to the expected term of the options. Expected Dividend – The Company has not declared dividends and does not anticipate declaring any dividends in the foreseeable future. Therefore, the Company uses a zero value for the expected dividend value factor to determine the fair value of options granted. Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with the same expected term. Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures. Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may significantly improve existing products or processes are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no future benefit are expensed when incurred. A cquired In-Process Research and Development Acquired in-process research and development (“clinical protocols”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests clinical protocols for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the clinical protocols intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the clinical protocol intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. The Company conducted the fiscal 2016 annual impairment assessment as of April 1, 2016. As the fair value exceeded book value, the Company concluded there was no impairment of the subject clinical protocol. Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred. Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not experienced significant credit related losses. Segment Reporting The Company has one reportable business segment: the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. Income Taxes The tax years 2012-2014 remain open to examination by the major taxing jurisdictions to which the Company is subject; however, there is no current examination. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes. There were no unrecognized tax benefits during the periods presented. The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not to be realized. The Company evaluates the need to retain all or a portion of the valuation allowance on recorded deferred tax assets. When a change in the tax rate or tax law has an impact on deferred taxes, the Company applies the change based on the years in which the temporary differences are expected to reverse. As the Company operates in more than one state, changes in the state apportionment factors, based on operational results, may affect future effective tax rates and the value of recorded deferred tax assets and liabilities. The Company records a change in tax rates in the consolidated financial statements in the period of enactment. Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets. Net Loss per Share Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2016 2015 Common stock equivalents of convertible debentures 3,676,471 -- Vested Series A warrants 404,412 -- Unvested Series A warrants 698,529 (1) -- Warrants – other 3,725,782 252,620 Stock options 104,378 147,609 Restricted stock awards 63,566 72,589 Total 8,673,138 472,818 (1) The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021. Reclassification Certain account totals and other figures from prior year have been reclassified to conform to current period presentation. Recently Adopted Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2015-03, " Interest -Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In August 2014, the FASB issued ASU 2014-15, “ Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Recently Issued Accounting Pronouncements In August 2016, the FASB issued ASU 2016-15, “ Classification of Certain Cash Receipts and Cash Payment s” Accounting Standards Codification Statement of Cash Flows ” . In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”. Revenue from Contracts with Customers (Topic 606) In March 2016, the FASB issued ASU 2016-09, “ Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” In January 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, " Recognition and Measurement of Financial Assets and Liabilities In November 2015, the FASB issued ASU 2015-17, " Income Taxes - Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, “ Inventory: Simplifying the Measurement of Inventory In June 2014, FASB issued ASU No. 2014-12, “ Compensation - Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period Entities may apply the amendments in ASU 2014-12 (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying ASU 2014-12 as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Company is currently reviewing the provisions of ASU 2014-12 to determine if there will be any impact on its results of operations, cash flows or financial condition. In May 2014, the FASB issued ASU 2014-09, “ Revenue from Contracts with Customers (Topic 606)

Note 3 - Intangible Assets

Note 3 - Intangible Assets	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. Intangible Assets Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired: June 30, 2016 Weighted Average Amortization Period Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 29 $ 10 $ 19 Licenses 7 462 157 305 Customer relationships 3 424 335 89 Device registration 7 86 49 37 Covenants not to compete 5 955 454 501 Amortizable intangible assets 1,956 1,005 951 Clinical protocols 19,870 -- 19,870 Total $ 21,826 $ 1,005 $ 20,821 June 30, 2015 Weighted Average Amortization Period Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 30 $ 6 $ 24 Licenses 7 490 96 394 Customer relationships 3 449 206 243 Device registration 7 92 20 72 Covenants not to compete 5 955 263 692 Amortizable intangible assets 2,016 591 1,425 Clinical protocols 19,870 -- 19,870 Total $ 21,886 $ 591 $ 21,295 The change in the gross carrying amount is due to foreign currency exchange fluctuations. Amortization of intangible assets was $438 and $458 for the years ended June 30, 2016 and 2015. Clinical protocols have not yet been introduced to the market place and are therefore not yet subject to amortization. The Company’s estimated future amortization expense for subsequent years are as follows: Year Ended June 30, 2017 $ 358 2018 269 2019 197 2020 78 2021 49 Total $ 951

Note 4 - Equipment

Note 4 - Equipment	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Equipment Equipment consisted of the following at June 30: 2016 2015 Estimated Useful Life (in years) Machinery and equipment $ 6,604 $ 5,895 2.5 - 10 Computer and software 397 897 2 - 5 Office equipment 260 741 5 - 10 Leasehold improvements 149 339 Shorter of 5 years or remaining lease term 7,410 7,872 Less accumulated depreciation and amortization (4,448 ) (4,935 ) $ 2,962 $ 2,937 Depreciation and amortization expense for the years ended June 30, 2016 and 2015 was $630 and $850, respectively.

Note 5 - Convertible Debentures

Note 5 - Convertible Debentures	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Convertible Debentures Convertible debentures consist of the following as of June 30, 2016: Convertible debentures $ 12,500 Unamortized debt discount (9,851 ) Unamortized debt issue costs (160 ) Convertible debentures, net $ 2,489 February 2016 Financing Transaction In February 2016 in exchange for aggregate proceeds of $15 million, the Company sold and issued to Boyalife Investment Inc. and Boyalife (Hong Kong Limited) (i) 735,294 shares of common stock at a purchase price of $3.40 per share (the “Stock Price”) for gross proceeds of $2.5 million, (ii) Secured Convertible Debentures for $12.5 million (the “Debentures”) convertible into 3,676,471 shares of common stock and (iii) warrants to purchase 3,529,412 additional shares of common stock at an exercise price of $8.00 per share for a period of five years. The amount of warrants was based on 80% coverage of the shares issued or to be issued for the equity transaction in (i) and the debt transaction in (ii) above. The warrants are exercisable on August 13, 2016. Total issue costs of $220 were allocated proportionately between the debt and equity proceeds, $183 and $37, respectively. The Debentures will be due in three years or February 13, 2019 and bear simple interest at a rate per annum of 22% of the principal amount outstanding. The Debentures may not be prepaid prior to maturity without the prior consent of the investor. Additionally, the Company’s obligations under the Debentures are secured by a first priority, senior lien over all of the Company’s assets. In accordance with the terms of the nomination and voting agreement entered into in connection with the financing, Dr. Xiaochun Xu, Chairman and CEO of Boyalife Group and Chairman of Boyalife Investment Inc. and Boyalife (Hong Kong Limited), was appointed to the Board of Directors of the Company in March 2016. All outstanding principal and accrued and unpaid interest (as well as all interest that would have accrued after the conversion and up to and including maturity in the event conversion occurs prior to maturity) under the Debentures will be convertible into the Company’s common stock at the Stock Price per share at the option of the investor at maturity or prior to maturity if (i) for 15 days upon and after the time that the Company’s cash balance and short-term investments, net of short term debt, are less than $2.1 million, (ii) the Company effects certain changes in control, or (iii) the Company’s common stock is delisted from Nasdaq’s markets. All outstanding principal and accrued and unpaid interest under the Debentures will also be convertible into shares of the Company’s common stock at the Stock Price per share at the option of the Company at any time prior to maturity, provided that (i) the 20-day simple moving average price of the Company’s common stock on the date of conversion is at least 125% of the Stock Price and (ii) the volume weighted average trading price of the Company’s common stock has been greater than the Stock Price for ten consecutive days. The warrants were classified as an equity instrument. Accordingly, the Company valued the warrants using the Black-Scholes option pricing model with the following assumptions: closing stock price on the measurement date of $4.00; warrant term of five years based on contractual term of the warrant; expected volatility based on historical volatility of 91% and discount rate based on the U.S. Treasury zero-coupon issues with equivalent terms of 1.2%. For financial reporting purposes, the net proceeds from the debt of $12,319 was allocated first to the relative fair value of the warrants, amounting to $4,434, then to the intrinsic value of the beneficial conversion feature on the Debentures of $6,824, resulting in an initial carrying value of the Debentures of $1,061. The initial debt discount on the Debentures totaled $11,258 and is being amortized over the three year life of the Debentures. During the year ended June 30, 2016, the Company amortized $1,407 of the debt discount, $23 of the debt issue costs and accrued $1,031 in interest expense. In August 2016, the Company converted the Debentures to common stock. See subsequent events footnote 12. Thirty-Year Debenture Restructuring Transaction On August 31, 2015, the Company sold senior secured convertible debentures in a financing to raise up to $15,000 (“Thirty-Year Debentures”), Series A warrants to purchase up to 1,102,942 shares of the Company’s common stock at an exercise price equal to $13.60 per share for a period of five and one-half years (“Series A warrants”) and Series B warrants to purchase up to 606,618 shares of the Company’s common stock at an exercise price equal to $13.60 per share for a period of eighteen months (“Series B warrants”). At the initial closing on August 31, 2015, the Company received gross proceeds of $5,500 and 404,412 Series A warrants vested and 222,427 Series B warrants vested. The second closing for up to an additional $9,500 was dependent on a number of items including receipt by the Company of approval from the California Institute for Regenerative Medicine (“CIRM”) for a grant in the amount of $10,000, to support the Company’s pivotal trial for CLIRST III. The Company applied for the CIRM grant in August 2015. The Company withdrew its application for the CIRM grant. For financial reporting purposes, the net proceeds of $4,720 was allocated first to the residual fair value of the Series A warrants, amounting to $3,385, then to the residual fair value of the obligation to issue the Series B warrants of $897, the remaining value to the intrinsic value of the beneficial conversion feature on the Thirty-Year Debentures of $438, resulting in an initial carrying value of the Thirty-Year Debentures of $0. The initial debt discount on the Thirty-Year Debentures totaled $4,720 and was amortized over the 30 year life of the convertible debentures. The Company entered into a registration rights agreement pursuant to which the Company agreed to register all of the shares of common stock then issued and issuable upon conversion in full of the Thirty-Year Debentures and all warrant shares issuable upon exercise of the Series A warrants and Series B warrants. The holders were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, getting an effective and maintaining an effective registration statement, including the failure of the Company to have such registration statement declared effective by October 26, 2015. As the Company did not file an effective registration statement until November 24, 2015 and the Company was precluded by the SEC from registering all of the registrable securities on a single registration statement, management considered it probable that five months of liquidated damages would be due and accrued $1,100 during the year ended June 30, 2016. Management made one liquidated damages payment of $220 during the three months ended December 31, 2015. In connection with the February 2016 financing transaction described above, the Company concurrently entered into a Consent, Repayment and Release Agreement, pursuant to which the Company repaid the Thirty-Year Debentures and all related interest and liquidated damages. Upon the Company’s payment of $7.5 million, the Thirty-Year Debentures were deemed repaid in full and cancelled, all liquidated damages due and payable were deemed paid and satisfied in full, the registration rights agreement was terminated and the exercise price of the Series A warrants was changed from $13.60 to $8.00. The Company recomputed the fair value of the Series A warrants before and after the modification using the Binomial option pricing model with the following assumptions: expected volatility of 91%, discount rate of 1.2%, contractual term of 5 years and dividend rate of 0%. The loss on modification of $149 was recorded in the accompanying consolidated statements of operations and comprehensive loss. Pursuant to the terms of the Consent Repayment and Release Agreement, the holders of the Series B warrants made a single, one-time cashless exercise of Series B warrants for 125,000 shares of common stock. The Company recomputed the fair value of the Series B warrants using the Binomial option pricing model with the assumptions listed in Note 6 for February 16, 2016. All remaining Series B warrants valued at $159 were cancelled. This restructuring transaction occurred on February 16, 2016 and the Company recorded a loss on extinguishment of debt of $795 during the year ended June 30, 2016. The loss on extinguishment was calculated as follows: Payment $ 7,500 Repayment of Thirty-Year debentures (5,500 ) Payment of accrued liquidated damages and interest (897 ) Loss on modification of Series A warrants (149 ) Cancellation of Series B derivative obligation (159 ) Loss on extinguishment of debt $ 795 At the time of the repayment, the remaining debt discount of $4,648 and debt issue costs of $765 were fully amortized. For the year ended June 30, 2016, the Company amortized $4,720 of debt discount and $777 of debt issue costs. Beneficial Conversion Features The beneficial conversion feature value was calculated as the difference resulting from subtracting the effective conversion price from the market price of the common stock on the issuance date, multiplied by the number of common shares into which the initial funding of the Debentures or Thirty-Year Debentures are convertible. The Company believes that the investor’s ability to resell the common shares resulting from the conversion option is severely limited. As such, the Company did not consider the beneficial conversion feature to be an embedded derivative.

Note 6 - Derivative Obligations

Note 6 - Derivative Obligations	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	6. Derivative Obligations Series A and Series B Warrants Series A warrants and Series B warrants to purchase 404,412 and 222,427 common shares, respectively, were issued and vested during the year ended June 30, 2016 (see Note 5). At the time of issuance, the Company determined that as such warrants can be settled for cash at the holders’ option in a future fundamental transaction they constituted a derivative liability. The Company estimated the fair value of the derivative liability aggregating approximately $4,282, using a Binomial Lattice Valuation Model and the following assumptions: Series A Series B August 31, 2015 June 30, 2016 August 31, 2015 February 16, Market price of common stock $ 13.60 $ 2.93 $ 13.60 $ 4.00 Expected volatility 72 % 99 % 62 % 137 % Contractual term (years) 5.5 4.7 1.5 1 Discount rate 1.54 % 1.01 % 0.57 % 0.5 % Dividend rate 0 % 0 % 0 % 0 % Exercise price $ 13.60 $ 8.00 $ 13.60 $ 13.60 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a gain of approximately $3,395 during the year ended June 30, 2016, representing the net change in the fair value of the derivative liability, which is presented as fair value change of derivative instruments, in the accompanying consolidated statements of operations and comprehensive loss. On February 16, 2016, the holders of the Series B warrants exercised 26,528 warrants on a cashless basis and received 125,000 shares of common stock. These warrants had an aggregate exercise date fair value of $25. The Company recomputed the fair value of these warrants using the Binomial option pricing model with the assumptions noted above for February 16, 2016. During the year ended June 30, 2016, an additional 25,185 Series B warrants were exercised on a cashless basis and the holders of the warrants received 106,711 shares of common stock. These warrants had an aggregate exercise date fair value of $33. The Company recomputed the fair value of these warrants using the Binomial option pricing model (Level 3 inputs) using the following weighted average assumptions: expected volatility of 88%, discount rate of 0.57%, contractual term of 1.2 years and dividend rate of 0%. The Company recorded a loss on cashless exercise of warrants of $1,039 for the year ended June 30, 2016, based on the difference between the fair market value of the Company’s common stock at the time of exercise and the fair value of the warrants exercised. In conjunction with the Consent, Repayment and Release Agreement, the Series A exercise price was changed from $13.60 to $8.00 and the remaining Series B warrants were cancelled (see Note 5). In accordance with U.S. GAAP, the following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2016: Balance at June 30, 2016 Level 1 Level 2 Level 3 Derivative obligation $ 670 $ - $ - $ 670 The following table reflects the change in fair value of the Company’s derivative liabilities for the year ended June 30, 2016: Amount Balance – July 1, 2015 $ -- Addition of derivative obligation at fair value on date of issuance 4,282 Reclassification of derivative obligation for exercised warrants (58 ) Extinguishment of derivative obligation (159 ) Change in fair value of derivative obligation (3,395 ) Balance – June 30, 2016 $ 670

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Operating Leases The Company leases the Rancho Cordova, Emeryville and Gurgaon, India facilities pursuant to operating leases, which contain scheduled rent increases. The leases expire in May 2019, September 2016 and March 2018, respectively. The Company recognizes rent expense on a straight-line basis over the term of the facility lease. The annual future minimum lease payments for the Company’s non-cancelable operating leases are as follows: 2017 428 2018 305 2019 260 Total $ 993 Rent expense was $657 and $652 for the years ended June 30, 2016 and 2015, respectively. Financial Covenants Effective September 30, 2015, the Company entered into a Fifth Amended and Restated Technology License and Escrow Agreement with Cord Blood Registry Systems, Inc. which modified the financial covenant that the Company must meet in order to avoid an event of default: cash balance and short-term investments net of debt or borrowed funds that are payable within one year of not less than $2,000 must be maintained. The Company is in compliance with this financial covenant as of June 30, 2016. Employee and Severance Agreements As of June 30, 2016, the Company had employment agreements in place with two of its key executives. The agreements provide, among other things, for the payment of twelve to twenty-four months of severance compensation for termination under certain circumstances. With respect to these agreements at June 30, 2016, potential severance amounted to $1,147. In September 2015, in connection with the resignation of the Company’s President, the Company and the President entered into a general release and waiver agreement in which the Company agreed to make severance payments over 18 months as long as the President actively abided by the terms of the agreement. As of June 30, 2016, approximately $265 remained to be paid out under this agreement. Contingencies In the normal course of operations, the Company may have disagreements or disputes with customers, employees or vendors. Such potential disputes are seen by management as a normal part of business. As of June 30, 2016, management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows. Warranty The Company offers a warranty on all of the Company’s non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of the Company’s recorded warranty liabilities and adjusts the amounts as necessary. Changes in the Company’s product liability which is included in other current liabilities during the period are as follows: For years ended June 30, 2016 2015 Beginning balance $ 627 $ 498 Warranties issued during the period 97 258 Settlements made during the period (287 ) (168 ) Changes in liability for pre-existing warranties during the period 129 39 Ending balance $ 566 $ 627

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	8. Stockholders’ Equity Warrants A summary of warrant activity is as follows: 2016 2015 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 252,620 $ 44.18 255,671 $ 44.18 Warrants granted 5,238,971 $ 9.83 -- -- Warrants exercised (cashless) (51,712 ) $ 13.60 -- -- Warrants expired/canceled (611,156 ) $ 17.21 (3,051 ) $ 43.00 Outstanding at June 30 4,828,723 $ 9.37 252,620 $ 44.18 Exercisable at June 30 600,782 $ 19.02 252,620 $ 44.18 Equity Plans and Agreements On July 7, 2016, the Compensation Committee of the Board of Directors adopted the 2016 Equity Incentive Plan (“2016 Plan”) under which up to 325,000 shares may be issued pursuant to grants of shares, options, or other forms of incentive compensation. The 2016 Plan remains subject to stockholder approval, which must be received by July 7, 2017. The 2012 Independent Director Plan (“2012 Plan”) permits the grant of stock or options to independent directors. A total of 25,000 shares were approved by the stockholders for issuance under the 2012 Plan. Options are granted at prices that are equal to 100% of the fair market value on the date of grant, and expire over a term not to exceed ten years. Options generally vest in monthly increments over one year, unless otherwise determined by the Board of Directors. As of June 30, 2016, there were 3,209 shares available for issuance. The 2006 Equity Incentive Plan (“2006 Plan”) permits the grant of options, restricted stock, stock bonuses and stock appreciation rights to employees, directors and consultants. Under the 2006 Plan, the number of shares of common stock equal to 6% of the number of outstanding shares of the Company, are authorized to be issued. The number of shares available to grant for awards adjusts at the beginning of each fiscal year if additional options to purchase shares of common stock were issued in the preceding fiscal year. As of June 30, 2016, there have been 392,320 shares approved under the 2006 Plan for issuance and 177,189 available for issuance. On July 7, 2016, the Compensation Committee also adopted a short term incentive plan under which cash awards and shares of common stock may be granted to employees of the Company (the “Short Term Plan”). The aggregate amount of the cash awards issuable pursuant to the Short Term Plan is approximately $276. Up to 104,000 shares of common stock from the Company’s 2006 Plan, subject to vesting, are issuable pursuant to the Short Term Plan. On July 26, 2016, 93,002 shares and $266 of cash awards were granted under the Short Term Plan. The cash awards granted pursuant to the Short Term Plan will be payable and the shares of common stock issued pursuant to the Short Term Plan will fully vest on July 1, 2017, provided, that such award recipients are employed by the Company as of such date or immediately if terminated without cause. The named executive officers of the Company are participating in the Short Term Plan. Upon the appointment as Chief Executive Officer (CEO) in June 2015, in accordance with his employment agreement, the Company’s CEO received restricted stock units representing 50,000 shares of restricted common stock vesting in four equal installments based upon a combination of time and milestone based targets and a seven year option to acquire 50,000 shares of common stock, 25% of which vested immediately with the balance vesting in equal monthly installments during the following 24 months. Stock Options Upon the separation with the Company’s former Chief Executive Officer in October 2014, in accordance with his employment agreement, all outstanding options and restricted stock awards which would have otherwise vested by July 31, 2015, immediately vested. As a result, the Company recognized $158 of stock compensation expense in general and administrative during the year ended June 30, 2015 as the vesting accelerated on 8,334 options and 3,500 restricted stock awards. Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at June 30, 2015 147,609 $ 25.51 Granted 55,875 $ 9.64 Forfeited/cancelled (93,855 ) $ 27.02 Expired (5,251 ) $ 41.47 Exercised -- -- Outstanding at June 30, 2016 104,378 $ 14.85 5.8 $ -- Vested and Expected to Vest at June 30, 2016 91,810 $ 15.34 5.7 $ -- Exercisable at June 30, 2016 61,271 $ 16.15 5.5 $ -- The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock. There were no options that were exercised during the years ended June 30, 2016 and 2015. Non-vested stock option activity for the year ended June 30, 2016, is as follows: Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at June 30, 2015 89,198 $ 13.07 Granted 55,875 $ 5.75 Vested (53,496 ) $ 9.79 Forfeited (48,470 ) $ 13.35 Outstanding at June 30, 2016 43,107 $ 7.66 The fair value of the Company’s stock options granted for the years ended June 30, 2016 and 2015 was estimated using the following weighted-average assumptions: 2016 2015 Expected life (years) 5 5 Risk-free interest rate 1.5 % 1.5 % Expected volatility 80 % 75 % Dividend yield 0 % 0 % The weighted average grant date fair value of options granted during the years ended June 30, 2016 and 2015 was $5.75 and $12.40, respectively. At June 30, 2016, the total compensation cost related to options granted under the Company's stock option plans but not yet recognized was $212. This cost will be amortized on a straight-line basis over a weighted-average period of approximately one and a half years and will be adjusted for subsequent changes in estimated forfeitures. The total fair value of options vested during the years ended June 30, 2016 and 2015 was $354 and $678. Common Stock Restricted Awards The following is a summary of restricted stock activity: 2016 2015 Number of Shares Weighted- Average Grant Date Fair Value Number of Shares Weighted- Average Grant Date Fair Value Balance at June 30 72,589 $ 22.40 40,190 $ 38.00 Granted 10,000 $ 2.98 54,850 $ 16.60 Vested (6,120 ) $ 28.94 (18,828 ) $ 36.40 Forfeited (12,903 ) $ 41.15 (3,623 ) $ 35.40 Outstanding at June 30 63,566 $ 14.96 72,589 $ 22.40 In connection with the vesting of the restricted stock awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 1,300 and 6,098 shares for the years ended June 30, 2016 and 2015, respectively and used the deemed proceeds from those shares to pay the income tax withholding. The net share settlement is deemed to be a repurchase by the Company of its common stock. As of June 30, 2016, the Company had $375 in total unrecognized compensation expense related to the Company’s restricted stock awards, which will be recognized over a weighted average period of approximately six months.

Note 9 - Concentrations

Note 9 - Concentrations	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	9. Concentrations One distributor had an accounts receivable balance of $901 or 28% and $1,423 or 28% at June 30, 2016 and 2015, respectively. A customer had an accounts receivable balance of $620 or 19% and $615 or 12% at June 30, 2016 and 2015, respectively. A second distributor had an accounts receivable balance of $320 or 10% and $520 or 10% at June 30, 2016 and 2015, respectively. A third distributor had an accounts receivable balance of $697 or 14% at June 30, 2015. Revenues from one distributor totaled $2,797 or 23% and $2,358 or 15% of net revenues for the years ended June 30, 2016 and 2015, respectively. Revenues from a customer totaled $2,475 or 21% and $2,549 or 16% for the years ended June 30, 2016 and 2015, respectively. Revenues from another distributor totaled $2,303 or 14% of net revenues for the year ended June 30, 2015. The following represents the Company’s revenues by product platform for the years ended June 30: 2016 2015 AXP $ 6,932 $ 6,612 BioArchive 2,465 4,241 Manual Disposables 1,507 1,810 Bone Marrow 459 2,621 Other 566 758 $ 11,929 $ 16,042 The Company had sales to customers as follows for the years ended June 30: 2016 2015 United States $ 5,122 $ 8,428 China 2,797 2,500 Asia - other 1,955 1,955 Europe 1,343 2,147 Other 712 1,012 $ 11,929 $ 16,042 The Company attributes revenue to different geographic areas based on where items are shipped or services are performed. Two suppliers accounted for 65% and 21% of total inventory purchases during the year ended June 30, 2016 and three suppliers accounted for 45%, 17% and 13% of total inventory purchases during the year ended June 30, 2015. The Company has a contract manufacturer in Costa Rica that produces certain disposables. The Company provides AXP equipment to its distributor in China for use by end-user customers. The Company’s equipment, net of accumulated depreciation, is summarized below by geographic area: June 30, 2016 June 30, 2015 United States $ 2,030 $ 1,409 Costa Rica 367 594 India 279 296 China 225 524 All other countries 61 114 Total equipment, net $ 2,962 $ 2,937

Note 10 - Income Taxes

Note 10 - Income Taxes	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Income Taxes Loss before income tax benefits was comprised of $17,789 from US and $799 from foreign jurisdictions in 2016 and $14,041 from US and $811 from foreign jurisdictions in 2015. The reconciliation of federal income tax attributable to operations computed at the federal statutory tax rate of 34% to income tax benefit is as follows for the years ended June 30: 2016 2015 Statutory federal income tax benefit $ (6,300 ) $ (5,046 ) Unbenefited net operating losses and credits 3,391 5,091 Disallowed financing costs 2,607 -- State and local taxes 69 (33 ) Other 233 (12 ) Total income tax expense $ -- $ -- A deferred income tax expense of $0 was recorded for the year ended June 30, 2016. No tax benefit has been recorded through June 30, 2016 because of the net operating losses incurred and a full valuation allowance has been provided. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. At June 30, 2016, the Company had net operating loss carryforwards for federal and state income tax purposes of $110,819 and $45,284 respectively that are available to offset future income. The federal and state loss carryforwards expire in various years between 2017 and 2036. At June 30, 2016, the Company has research and experimentation credit carryforwards of $1,418 for federal tax purposes that expire in various years between 2019 and 2036, and $1,437 for state income tax purposes that do not have an expiration date. Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes are as follows: June 30, 2016 June 30, 2015 Deferred tax assets: Net operating loss carryforwards $ 41,023 $ 38,317 Income tax credit carryforwards 2,367 2,143 Stock compensation 874 916 Other 1,345 1,479 Valuation allowance (45,892 ) (42,408 ) Total deferred taxes (283 ) 447 Deferred tax liabilities Depreciation and amortization (7,358 ) (8,088 ) Net deferred taxes and liabilities $ (7,641 ) $ (7,641 ) The valuation allowance increased by $3,484 in 2016. As of June 30, 2016, the Company has a benefit of $219 related to stock option deductions, which will be credited to paid-in capital when realized. In August 2016, the conversion of the debentures with Boyalife Investment Inc. (see subsequent events footnote 12) effected an “ownership change” as defined under the provisions of the Tax Reform Act of 1986. As a result, any net operating loss and credit carryovers existing at that date will be subject to an annual limitation regarding their utilization against taxable income in future periods. Additionally, before the conversion of the debentures, it is possible that “ownership changes” occurred, which could create additional imitations on the use of our net operating losses and credit carryovers.

Note 11 - Employee Retirement P

Note 11 - Employee Retirement Plan	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	11 . Employee Retirement Plan The Company sponsors an Employee Retirement Plan, generally available to all employees, in accordance with Section 401(k) of the Internal Revenue Code. Employees may elect to contribute up to the Internal Revenue Service annual contribution limit. Under this Plan, at the discretion of the Board of Directors, the Company may match a portion of the employees’ contributions. The Company made no discretionary or matching contributions to the Plan for the years ended June 30, 2016 and 2015.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	12 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	12. Subsequent Event s On August 3, 2016, the Company sold 600,000 shares of common stock at a price of $4.10 per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the estimated offering expenses borne by the Company are expected to be approximately $2.2 million. On August 22, 2016, the Company notified Boyalife Investment Inc., that it elected to convert all outstanding principal and interest accrued and otherwise payable under the Debentures, which included the conversion of $12,500 of principal and $8,250 of interest up to and including the maturity date of the Debentures. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures and all security interest and liens were terminated.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Organization and Basis of Presentation Cesca Therapeutics Inc. (Cesca, the Company) develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. Cesca is a leader in developing and manufacturing automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On March 4, 2016, the Company effected a one (1) for twenty (20) reverse split of its issued and outstanding common stock. There were no changes to its authorized number of shares of common stock of 350,000,000. All historical share amounts disclosed herein have been retroactively recast to reflect the reverse split. No fractional shares were issued; fractional shares of common stock were rounded up to the nearest whole share.
Liquidity [Policy Text Block]	Liquidity On August 3, 2016, the Company sold 600,000 shares of common stock at a price of $4.10 per share. The net proceeds to the Company from the sale and issuance of the shares, after deducting the estimated offering expenses borne by the Company are expected to be approximately $2.2 million. On August 22, 2016, the Company elected to convert all outstanding principal and interest accrued and otherwise payable under the secured convertible debentures. Upon conversion, 6,102,941 shares of common stock were issued and the Debentures and all security interest and liens were terminated. At June 30, 2016, the Company had cash and cash equivalents of $5,835 and working capital of $7,301. The Company has incurred recurring operating losses and as of June 30, 2016 had an accumulated deficit of $156,262. The Company has primarily financed operations to date through the sale of equity securities and the sale of certain non-core assets. In February 2016, the Company completed a financing transaction (“the Financing Transaction”) for gross proceeds of $15 million. Half, or $7.5 million, of the proceeds were used to pay the investors in the August 2015 financing to repay the convertible debentures, liquidated damages and interest. Net proceeds after the repayment and issue costs were $7.3 million. Based upon the Company’s cash balance, the August 2016 Financing, historical trends, expected outflows and projections for revenues, management believes it will have sufficient cash to provide for its projected needs to maintain operations and working capital requirements for at least the next 12 months from the date of filing this annual report. The Company will need additional funding to support its phase III Critical Limb Ischemia (CLIRST III) trial. As such, management has been exploring additional funding sources including strategic partner relationships. The Company cannot assure that such funding will be available on a timely basis, in needed quantities, or on favorable terms, if at all.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of Cesca Therapeutics Inc., and the Company’s wholly-owned subsidiaries, TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not limited to, the allowance for doubtful accounts, slow-moving inventory reserves, depreciation, warranty costs, assumptions made in valuing equity instruments issued for services or acquisitions, deferred income taxes and related valuation allowance and the fair values of intangibles and goodwill. Actual results could materially differ from the estimates and assumptions used in the preparation of the Company’s consolidated financial statements. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying consolidated financial statements through the date of issuance.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no conditional evaluation on any product sold and recognized as revenue. Amounts billed in excess of revenue recognized are recorded as deferred revenue on the balance sheet. The Company’s sales are generally through distributors. There is no right of return provided for distributors. For sales of products made to distributors, the Company considers a number of factors in determining whether revenue is recognized upon transfer of title to the distributor, or when payment is received. These factors include, but are not limited to, whether the payment terms offered to the distributor are considered to be non-standard, the distributor history of adhering to the terms of its contractual arrangements with us, the level of inventories maintained by the distributor, whether the Company has a pattern of granting concessions for the benefit of the distributor, and whether there are other conditions that may indicate that the sale to the distributor is not substantive. The Company currently recognizes revenue primarily on the sell-in method with its distributors. Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not available for a given unit of accounting. Significant inputs for the estimates of the selling price of separate units of accounting include market and pricing trends and a customer’s geographic location. The Company accounts for training and installation, and service agreements and the collection, processing and testing of the umbilical cord blood and the storage as separate units of accounting. Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 years. All other service revenue is recognized at the time the service is completed. Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company’s cash is maintained in checking accounts, money market funds and certificates of deposits with reputable financial institutions that may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation. The Company has cash and cash equivalents of $104 and $247 at June 30, 2016 and 2015, respectively in India. The Company has not experienced any realized losses on the Company’s deposits of cash and cash equivalents.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not necessarily agree with changes in the corresponding balances on the consolidated balance sheet. Equity accounts other than retained earnings are translated at the historic exchange rate on the date of investment. A translation loss of $32 and $63 was recorded for the years ended June 30, 2016 and 2015, respectively, as a component of other comprehensive income.
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not considered to have an indefinite useful life are amortized over their useful lives, which generally range from three to ten years. Clinical protocols are not expected to provide economic benefit until they are introduced to the marketplace or licensed to an independent entity. Each period the Company evaluates the estimated remaining useful lives of purchased intangible assets and whether events or changes in circumstances warrant a revision to the remaining periods of amortization. For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. According to ASC 350, Intangibles-Goodwill and Other The Company performed a quantitative assessment as of April 1, 2016 and computed a fair value based on a combination of the income approach and market approach, which determined that the fair value exceeded the carrying amount. Accordingly, there was no impairment of goodwill or the indefinite-lived intangible assets. For the definite-lived intangible assets, there were no facts or changes in circumstances that indicated the carrying value may not be recoverable. As such, no assessment was required and there was no impairment of these assets.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures set or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three levels of inputs that may be used to measure fair value: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 within the fair value hierarchy since the valuation model of the derivative obligation is based on unobservable inputs.
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third parties that will be settled in cash. The carrying value of the Company’s receivables, net of the allowance for doubtful accounts, represents their estimated net realizable value. The Company estimates the allowance for doubtful accounts based on historical collection trends, age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that a specific receivable balance may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. A customer’s receivable balance is considered past-due based on its contractual terms. Past-due receivable balances are written-off when the Company’s internal collection efforts have been unsuccessful in collecting the amount due.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out basis. The Company writes-down to its estimated net realizable value when conditions indicate that the selling price could be less than cost due to physical deterioration, obsolescence, changes in price levels, or other causes, which it includes as a component of cost of revenues. Additionally, the Company provides valuation allowances for excess and slow-moving inventory on hand that are not expected to be sold to reduce the carrying amount of slow-moving inventory to its estimated net realizable value. The valuation allowances are based upon estimates about future demand from its customers and distributors and market conditions. Because some of the Company’s products are highly dependent on government and third-party funding, current customer use and validation, and completion of regulatory and field trials, there is a risk that the Company will forecast incorrectly and purchase or produce excess inventories. As a result, actual demand may differ from forecasts and the Company may be required to record additional inventory valuation allowances that could adversely impact its gross margins. Conversely, favorable changes in demand could result in higher gross margins when those products are sold.
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight line method over their estimated useful lives or the remaining lease period, whichever is shorter.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure.
Debt, Policy [Policy Text Block]	Debt Issue Costs The Company amortizes debt issue costs to interest expense over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Debt Discount The Company amortizes debt discount over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Such amortized cost is included with the other income (expense) in the accompanying consolidated statements of operations.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may also issue freestanding warrants. If freestanding warrants are issued and accounted for as derivative instrument liabilities (rather than as equity), the proceeds are first allocated to the fair value of those instruments. The remaining proceeds, if any, are then allocated to the convertible instrument, usually resulting in that instrument being recorded at a discount from its face amount. Derivative financial instruments are initially measured at their fair value using a Binomial Lattice Valuation Model and then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company has two stock-based compensation plans, which are described more fully in Note 8. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not include a discount for post-vesting restrictions, as we have not issued awards with such restrictions. Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that corresponded to the expected term of the options. Expected Dividend – The Company has not declared dividends and does not anticipate declaring any dividends in the foreseeable future. Therefore, the Company uses a zero value for the expected dividend value factor to determine the fair value of options granted. Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with the same expected term. Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may significantly improve existing products or processes are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no future benefit are expensed when incurred.
Business Combinations Policy [Policy Text Block]	A cquired In-Process Research and Development Acquired in-process research and development (“clinical protocols”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a determination as to the then useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company tests clinical protocols for impairment at least annually, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of the clinical protocols intangible asset is less than its carrying amount. If the Company concludes it is more likely than not that the fair value is less than the carrying amount, a quantitative test that compares the fair value of the clinical protocol intangible asset with its carrying value is performed. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results. The Company conducted the fiscal 2016 annual impairment assessment as of April 1, 2016. As the fair value exceeded book value, the Company concluded there was no impairment of the subject clinical protocol.
Legal Costs, Policy [Policy Text Block]	Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not experienced significant credit related losses.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company has one reportable business segment: the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine.
Income Tax, Policy [Policy Text Block]	Income Taxes The tax years 2012-2014 remain open to examination by the major taxing jurisdictions to which the Company is subject; however, there is no current examination. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes. There were no unrecognized tax benefits during the periods presented. The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not to be realized. The Company evaluates the need to retain all or a portion of the valuation allowance on recorded deferred tax assets. When a change in the tax rate or tax law has an impact on deferred taxes, the Company applies the change based on the years in which the temporary differences are expected to reverse. As the Company operates in more than one state, changes in the state apportionment factors, based on operational results, may affect future effective tax rates and the value of recorded deferred tax assets and liabilities. The Company records a change in tax rates in the consolidated financial statements in the period of enactment. Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2016 2015 Common stock equivalents of convertible debentures 3,676,471 -- Vested Series A warrants 404,412 -- Unvested Series A warrants 698,529 (1) -- Warrants – other 3,725,782 252,620 Stock options 104,378 147,609 Restricted stock awards 63,566 72,589 Total 8,673,138 472,818 (1) The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.
Reclassification, Policy [Policy Text Block]	Reclassification Certain account totals and other figures from prior year have been reclassified to conform to current period presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2015-03, " Interest -Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs In August 2014, the FASB issued ASU 2014-15, “ Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern
Recently Issued Accounting Pronouncements [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2016, the FASB issued ASU 2016-15, “ Classification of Certain Cash Receipts and Cash Payment s” Accounting Standards Codification Statement of Cash Flows ” . In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients”. Revenue from Contracts with Customers (Topic 606) In March 2016, the FASB issued ASU 2016-09, “ Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” In January 2016, the FASB issued Accounting Standards Update (ASU) 2016-01, " Recognition and Measurement of Financial Assets and Liabilities In November 2015, the FASB issued ASU 2015-17, " Income Taxes - Balance Sheet Classification of Deferred Taxes In July 2015, the FASB issued ASU No. 2015-11, “ Inventory: Simplifying the Measurement of Inventory In June 2014, FASB issued ASU No. 2014-12, “ Compensation - Stock Compensation (Topic 718); Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period Entities may apply the amendments in ASU 2014-12 (a) prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying ASU 2014-12 as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. Additionally, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Company is currently reviewing the provisions of ASU 2014-12 to determine if there will be any impact on its results of operations, cash flows or financial condition. In May 2014, the FASB issued ASU 2014-09, “ Revenue from Contracts with Customers (Topic 606)

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2016 2015 Common stock equivalents of convertible debentures 3,676,471 -- Vested Series A warrants 404,412 -- Unvested Series A warrants 698,529 (1) -- Warrants – other 3,725,782 252,620 Stock options 104,378 147,609 Restricted stock awards 63,566 72,589 Total 8,673,138 472,818

Note 3 - Intangible Assets (Tab

Note 3 - Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2016 Weighted Average Amortization Period Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 29 $ 10 $ 19 Licenses 7 462 157 305 Customer relationships 3 424 335 89 Device registration 7 86 49 37 Covenants not to compete 5 955 454 501 Amortizable intangible assets 1,956 1,005 951 Clinical protocols 19,870 -- 19,870 Total $ 21,826 $ 1,005 $ 20,821 June 30, 2015 Weighted Average Amortization Period Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 30 $ 6 $ 24 Licenses 7 490 96 394 Customer relationships 3 449 206 243 Device registration 7 92 20 72 Covenants not to compete 5 955 263 692 Amortizable intangible assets 2,016 591 1,425 Clinical protocols 19,870 -- 19,870 Total $ 21,886 $ 591 $ 21,295
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended June 30, 2017 $ 358 2018 269 2019 197 2020 78 2021 49 Total $ 951

Note 4 - Equipment (Tables)

Note 4 - Equipment (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	2016 2015 Estimated Useful Life (in years) Machinery and equipment $ 6,604 $ 5,895 2.5 - 10 Computer and software 397 897 2 - 5 Office equipment 260 741 5 - 10 Leasehold improvements 149 339 Shorter of 5 years or remaining lease term 7,410 7,872 Less accumulated depreciation and amortization (4,448 ) (4,935 ) $ 2,962 $ 2,937

Note 5 - Convertible Debentur23

Note 5 - Convertible Debentures (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Convertible Debt [Table Text Block]	Convertible debentures $ 12,500 Unamortized debt discount (9,851 ) Unamortized debt issue costs (160 ) Convertible debentures, net $ 2,489
Schedule of Extinguishment of Debt [Table Text Block]	Payment $ 7,500 Repayment of Thirty-Year debentures (5,500 ) Payment of accrued liquidated damages and interest (897 ) Loss on modification of Series A warrants (149 ) Cancellation of Series B derivative obligation (159 ) Loss on extinguishment of debt $ 795

Note 6 - Derivative Obligatio24

Note 6 - Derivative Obligations (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Series A Series B August 31, 2015 June 30, 2016 August 31, 2015 February 16, Market price of common stock $ 13.60 $ 2.93 $ 13.60 $ 4.00 Expected volatility 72 % 99 % 62 % 137 % Contractual term (years) 5.5 4.7 1.5 1 Discount rate 1.54 % 1.01 % 0.57 % 0.5 % Dividend rate 0 % 0 % 0 % 0 % Exercise price $ 13.60 $ 8.00 $ 13.60 $ 13.60
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Balance at June 30, 2016 Level 1 Level 2 Level 3 Derivative obligation $ 670 $ - $ - $ 670
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – July 1, 2015 $ -- Addition of derivative obligation at fair value on date of issuance 4,282 Reclassification of derivative obligation for exercised warrants (58 ) Extinguishment of derivative obligation (159 ) Change in fair value of derivative obligation (3,395 ) Balance – June 30, 2016 $ 670

Note 7 - Commitments and Cont25

Note 7 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2017 428 2018 305 2019 260 Total $ 993
Schedule of Product Warranty Liability [Table Text Block]	For years ended June 30, 2016 2015 Beginning balance $ 627 $ 498 Warranties issued during the period 97 258 Settlements made during the period (287 ) (168 ) Changes in liability for pre-existing warranties during the period 129 39 Ending balance $ 566 $ 627

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2016 2015 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted- Average Exercise Price Per Share Beginning balance 252,620 $ 44.18 255,671 $ 44.18 Warrants granted 5,238,971 $ 9.83 -- -- Warrants exercised (cashless) (51,712 ) $ 13.60 -- -- Warrants expired/canceled (611,156 ) $ 17.21 (3,051 ) $ 43.00 Outstanding at June 30 4,828,723 $ 9.37 252,620 $ 44.18 Exercisable at June 30 600,782 $ 19.02 252,620 $ 44.18
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at June 30, 2015 147,609 $ 25.51 Granted 55,875 $ 9.64 Forfeited/cancelled (93,855 ) $ 27.02 Expired (5,251 ) $ 41.47 Exercised -- -- Outstanding at June 30, 2016 104,378 $ 14.85 5.8 $ -- Vested and Expected to Vest at June 30, 2016 91,810 $ 15.34 5.7 $ -- Exercisable at June 30, 2016 61,271 $ 16.15 5.5 $ --
Non Vested Stock Options Activity [Table Text Block]	Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at June 30, 2015 89,198 $ 13.07 Granted 55,875 $ 5.75 Vested (53,496 ) $ 9.79 Forfeited (48,470 ) $ 13.35 Outstanding at June 30, 2016 43,107 $ 7.66
Schedule of Assumptions Used [Table Text Block]	2016 2015 Expected life (years) 5 5 Risk-free interest rate 1.5 % 1.5 % Expected volatility 80 % 75 % Dividend yield 0 % 0 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	2016 2015 Number of Shares Weighted- Average Grant Date Fair Value Number of Shares Weighted- Average Grant Date Fair Value Balance at June 30 72,589 $ 22.40 40,190 $ 38.00 Granted 10,000 $ 2.98 54,850 $ 16.60 Vested (6,120 ) $ 28.94 (18,828 ) $ 36.40 Forfeited (12,903 ) $ 41.15 (3,623 ) $ 35.40 Outstanding at June 30 63,566 $ 14.96 72,589 $ 22.40

Note 9 - Concentrations (Tables

Note 9 - Concentrations (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	2016 2015 AXP $ 6,932 $ 6,612 BioArchive 2,465 4,241 Manual Disposables 1,507 1,810 Bone Marrow 459 2,621 Other 566 758 $ 11,929 $ 16,042
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	2016 2015 United States $ 5,122 $ 8,428 China 2,797 2,500 Asia - other 1,955 1,955 Europe 1,343 2,147 Other 712 1,012 $ 11,929 $ 16,042
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	June 30, 2016 June 30, 2015 United States $ 2,030 $ 1,409 Costa Rica 367 594 India 279 296 China 225 524 All other countries 61 114 Total equipment, net $ 2,962 $ 2,937

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2016 2015 Statutory federal income tax benefit $ (6,300 ) $ (5,046 ) Unbenefited net operating losses and credits 3,391 5,091 Disallowed financing costs 2,607 -- State and local taxes 69 (33 ) Other 233 (12 ) Total income tax expense $ -- $ --
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30, 2016 June 30, 2015 Deferred tax assets: Net operating loss carryforwards $ 41,023 $ 38,317 Income tax credit carryforwards 2,367 2,143 Stock compensation 874 916 Other 1,345 1,479 Valuation allowance (45,892 ) (42,408 ) Total deferred taxes (283 ) 447 Deferred tax liabilities Depreciation and amortization (7,358 ) (8,088 ) Net deferred taxes and liabilities $ (7,641 ) $ (7,641 )

Note 1 - Description of Busin29

Note 1 - Description of Business and Basis of Presentation (Details Textual) $ / shares in Units, $ in Thousands	Aug. 22, 2016shares	Aug. 03, 2016USD ($)$ / sharesshares	Mar. 04, 2016shares	Feb. 29, 2016USD ($)shares	Jun. 30, 2016USD ($)shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			20
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares		600,000
Shares Issued, Price Per Share | $ / shares		$ 4.10
Proceeds from Issuance of Common Stock		$ 2,200
Debt Conversion, Converted Instrument, Shares Issued | shares	6,102,941
Common Stock, Shares Authorized | shares			350,000,000		350,000,000	350,000,000
Stock Issued During Period, Shares, New Issues | shares				735,294
Proceeds from Issuance of Common Stock					$ 2,463
Cash and Cash Equivalents, at Carrying Value					5,835	3,357	$ 14,811
Working Capital					7,301
Retained Earnings (Accumulated Deficit)					(156,262)	(137,674)
Gross Proceeds from Financing Transaction				$ 15,000
Repayments of Convertible Debt				7,500	$ 6,444
Net Proceeds from Financing Transaction				$ 7,300

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Feb. 29, 2016USD ($)	Jun. 30, 2014USD ($)
INDIA
Cash and Cash Equivalents, at Carrying Value	$ 104,000	$ 247,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		10 years
Maximum Period Of Agreement	21 years
Cash and Cash Equivalents, at Carrying Value	$ 5,835,000	$ 3,357,000		$ 14,811,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	(32,000)	$ (63,000)
Goodwill, Impairment Loss	0
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0
Impairment of Intangible Assets, Finite-lived	$ 0
Number of Reportable Segments	1
Debt Issuance Costs, Net	$ 160,000		$ 220,000

Note 2 - Calculation for Basic

Note 2 - Calculation for Basic and Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Jun. 30, 2016		Jun. 30, 2015
Convertible Debt Securities [Member]
Common stock equivalents of convertible debentures (in shares)	3,676,471
Vested Series A warrants [Member]
Common stock equivalents of convertible debentures (in shares)	404,412
Unvested Series A warrants [Member]
Common stock equivalents of convertible debentures (in shares)	698,529	[1]
Warrant, Other [Member]
Common stock equivalents of convertible debentures (in shares)	3,725,782		252,620
Employee Stock Option [Member]
Common stock equivalents of convertible debentures (in shares)	104,378		147,609
Restricted Stock Units (RSUs) [Member]
Common stock equivalents of convertible debentures (in shares)	63,566		72,589
Common stock equivalents of convertible debentures (in shares)	8,673,138		472,818
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Intangible Assets (Det

Note 3 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Amortization of Intangible Assets	$ 438	$ 458

Note 3 - Intangible Assets Disc

Note 3 - Intangible Assets Disclosure (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Gross Carrying Amount	$ 29	$ 30
Accumulated Amortization	10	6
Net	$ 19	$ 24
Licensing Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Gross Carrying Amount	$ 462	$ 490
Accumulated Amortization	157	96
Net	$ 305	$ 394
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	3 years	3 years
Gross Carrying Amount	$ 424	$ 449
Accumulated Amortization	335	206
Net	$ 89	$ 243
Device Registration [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Gross Carrying Amount	$ 86	$ 92
Accumulated Amortization	49	20
Net	$ 37	$ 72
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	5 years	5 years
Gross Carrying Amount	$ 955	$ 955
Accumulated Amortization	454	263
Net	501	692
Clinical Protocols [Member]
Gross Carrying Amount	19,870	19,870
Accumulated Amortization
Net	19,870	19,870
Gross Carrying Amount	1,956	2,016
Accumulated Amortization	1,005	591
Net	951	1,425
Gross Carrying Amount	21,826	21,886
Net	$ 20,821	$ 21,295

Note 3 - Future Amortization Ex

Note 3 - Future Amortization Expense (Details) $ in Thousands	Jun. 30, 2016USD ($)
2,017	$ 358
2,018	269
2,019	197
2,020	78
2,021	49
Total	$ 951

Note 4 - Equipment (Details Tex

Note 4 - Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Depreciation	$ 630	$ 850

Note 4 - Property, Plant, and E

Note 4 - Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Machinery and Equipment [Member] | Minimum [Member]
Estimated Useful Life	2 years 182 days
Machinery and Equipment [Member] | Maximum [Member]
Estimated Useful Life	10 years
Machinery and Equipment [Member]
Property, Plant, and Equipment, Gross	$ 6,604	$ 5,895
Computer and Software [Member] | Minimum [Member]
Estimated Useful Life	2 years
Computer and Software [Member] | Maximum [Member]
Estimated Useful Life	5 years
Computer and Software [Member]
Property, Plant, and Equipment, Gross	$ 397	897
Office Equipment [Member] | Minimum [Member]
Estimated Useful Life	5 years
Office Equipment [Member] | Maximum [Member]
Estimated Useful Life	10 years
Office Equipment [Member]
Property, Plant, and Equipment, Gross	$ 260	741
Leasehold Improvements [Member] | Minimum [Member]
Estimated Useful Life	5 years
Leasehold Improvements [Member] | Maximum [Member]
Estimated Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant, and Equipment, Gross	$ 149	339
Property, Plant, and Equipment, Gross	7,410	7,872
Less accumulated depreciation and amortization	(4,448)	(4,935)
Property, Plant, and Equipment, Net	$ 2,962	$ 2,937

Note 5 - Convertible Debentur37

Note 5 - Convertible Debentures (Details Textual) - USD ($)	Feb. 29, 2016	Feb. 16, 2016	Feb. 29, 2016	Aug. 31, 2015	Dec. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Series A Warrant [Member] | Thirty-Year Debentures [Member]
Residual Fair Value of Warrants				$ 3,385,000
Series A Warrant [Member] | Other Expense [Member]
Derivative, Gain (Loss) on Derivative, Net	$ (149,000)
Series A Warrant [Member]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8		$ 8	$ 13.60
Warrant Expiration Period				5 years 182 days
Fair Value Assumptions, Expected Term	5 years
Fair Value Assumptions, Expected Volatility Rate	91.00%
Fair Value Inputs, Discount Rate	1.20%
Class of Warrant or Right, Outstanding				404,412		404,412
Warrants [Member]
Fair Value Assumptions, Expected Term			5 years
Fair Value Assumptions, Expected Volatility Rate			91.00%
Fair Value Inputs, Discount Rate			1.20%
Series B Warrant [Member] | Thirty-Year Debentures [Member]
Residual Fair Value of Warrants				$ 897,000
Class of Warrant or Right, Cancelled During Period,Value						$ 159,000
Series B Warrant [Member]
Fair Value Assumptions, Expected Dividend Rate						0.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				606,618
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 13.60
Warrant Expiration Period				1 year 180 days
Fair Value Assumptions, Expected Term						1 year 73 days
Fair Value Assumptions, Expected Volatility Rate						88.00%
Fair Value Inputs, Discount Rate						0.57%
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 25,000				$ 33,000
Class of Warrant or Right, Outstanding				222,427		222,427
Shares Issued for Cashless Exercise of Warrants		125,000				106,711
Class of Warrant or Right, Cancelled During Period,Value		$ 159,000
Convertible Debt [Member] | Debt Issuance Cost Allocated to Debt [Member]
Debt Issuance Costs, Net	$ 183,000		$ 183,000
Convertible Debt [Member] | Debt Issuance Cost Allocated to Equity [Member]
Debt Issuance Costs, Net	37,000		37,000
Convertible Debt [Member]
Debt Instrument, Face Amount	$ 12,500,000		$ 12,500,000
Debt Conversion, Convertible Shares	3,676,471		3,676,471
Debt Instrument, Term			3 years
Debt Instrument, Interest Rate, Stated Percentage	22.00%		22.00%
Proceeds from Convertible Debt			$ 12,319,000
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 4,434,000		4,434,000
Convertible Debt	1,061,000		1,061,000
Debt Instrument, Unamortized Discount	$ 11,258,000		11,258,000
Amortization of Debt Discount (Premium)						$ 1,407,000
Amortization of Debt Issuance Costs						23,000
Interest Expense						1,031,000
Debentures, Beneficial Conversion Feature [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature			6,824,000
Thirty-Year Debentures [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,102,942
Debt Instrument, Term				30 years
Proceeds from Convertible Debt				$ 4,720,000
Convertible Debt				0
Debt Instrument, Unamortized Discount				4,720,000
Amortization of Debt Discount (Premium)		4,648,000				4,720,000
Amortization of Debt Issuance Costs		$ 765,000				777,000
Potential Proceed from Issuance of Convertible Debt				15,000,000
Gross Proceeds from Convertible Debt				5,500,000		5,500,000
Registration Payment Arrangement, Gains and Losses						1,100,000
Registration Payment					$ 220,000
Repayments of Debt			7,500,000			7,500,000
Gain (Loss) on Extinguishment of Debt						$ (795,000)
Payment After Approval of Authorities [Member]
Potential Proceed from Issuance of Convertible Debt				9,500,000
Thirty-Year Debentures, Beneficial Conversion Feature [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature				438,000
Fair Value Assumptions, Expected Dividend Rate						0.00%	0.00%
Gross Proceeds from Financing Transaction			$ 15,000,000
Stock Issued During Period, Shares, New Issues			735,294
Sale of Stock, Price Per Share	$ 3.40		$ 3.40
Stock Issued During Period, Value, New Issues			$ 2,500,000			$ 2,464,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,529,412		3,529,412
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8		$ 8
Warrant Expiration Period			5 years
Number of Warrants, Percentage of Shares Issued or to Be Issued			80.00%
Debt Issuance Costs, Net	$ 220,000		$ 220,000			$ 160,000
Period after Benchmark Reached			15 days
Net Cash and Short-Term Investment Benchmark	$ 2,100,000		$ 2,100,000
Duration of Moving Average Price			20 days
Percent of Stock Price			125.00%
Consecutive Days of Weighted Average Trading Price			10 days
Share Price	$ 4		$ 4
Fair Value Assumptions, Expected Term						5 years	5 years
Fair Value Assumptions, Expected Volatility Rate						80.00%	75.00%
Proceeds from Convertible Debt						$ 18,000,000
Convertible Debt						2,489,000
Debt Instrument, Unamortized Discount						9,851,000
Amortization of Debt Discount (Premium)						6,127,000
Amortization of Debt Issuance Costs						800,000
Interest Expense						1,864,000	14,000
Approval for Grant in Amount for Clinical Trial				$ 10,000,000
Registration Payment Arrangement, Gains and Losses						(1,100,000)
Derivative, Gain (Loss) on Derivative, Net						3,395,000
Gain (Loss) on Extinguishment of Debt						$ (795,000)

Note 5 - Convertible Debentur38

Note 5 - Convertible Debentures Components (Details) $ in Thousands	Jun. 30, 2016USD ($)
Convertible debentures	$ 12,500
Unamortized debt discount	(9,851)
Unamortized debt issue costs	(160)
Convertible debentures, net	$ 2,489

Note 5 - Schedule of Extinguish

Note 5 - Schedule of Extinguishment of Debt (Details) - USD ($)	Feb. 16, 2016	Feb. 29, 2016	Aug. 31, 2015	Jun. 30, 2016	Jun. 30, 2015
Thirty-Year Debentures [Member] | Series A Warrant [Member]
Loss on modification of Series A warrants				$ (149,000)
Thirty-Year Debentures [Member] | Series B Warrant [Member]
Cancellation of Series B derivative obligation				(159,000)
Thirty-Year Debentures [Member]
Repayments of Debt		$ 7,500,000		7,500,000
Repayment of Thirty-Year debentures			$ (5,500,000)	(5,500,000)
Payment of accrued liquidated damages and interest				(897,000)
Loss on extinguishment of debt				795,000
Series B Warrant [Member]
Cancellation of Series B derivative obligation	$ (159,000)
Loss on modification of Series A warrants				149,000
Loss on extinguishment of debt				$ 795,000

Note 6 - Derivative Obligatio40

Note 6 - Derivative Obligations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 29, 2016	Feb. 16, 2016	Jun. 30, 2016	Jun. 30, 2015	Aug. 31, 2015
Series A Warrant [Member]
Class of Warrant or Right, Outstanding			404,412		404,412
Fair Value Assumptions, Expected Volatility Rate	91.00%
Fair Value Inputs, Discount Rate	1.20%
Fair Value Assumptions, Expected Term	5 years
Fair Value Assumptions, Expected Dividend Rate	0.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8				$ 13.60
Series B Warrant [Member]
Class of Warrant or Right, Outstanding			222,427		222,427
Warrants Exercised		26,528	25,185
Shares Issued for Cashless Exercise of Warrants		125,000	106,711
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 25	$ 33
Fair Value Assumptions, Expected Volatility Rate			88.00%
Fair Value Inputs, Discount Rate			0.57%
Fair Value Assumptions, Expected Term			1 year 73 days
Fair Value Assumptions, Expected Dividend Rate			0.00%
Gain (Loss) on Cashless Exercise of Warrants			$ (1,039)
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 13.60
Derivative Liability			4,282
Derivative, Gain (Loss) on Derivative, Net			$ 3,395
Fair Value Assumptions, Expected Volatility Rate			80.00%	75.00%
Fair Value Assumptions, Expected Term			5 years	5 years
Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%
Gain (Loss) on Cashless Exercise of Warrants			$ (1,039)
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8

Note 6 - Derivative Obligatio41

Note 6 - Derivative Obligations, Fair Value Assumptions (Details) - $ / shares	Aug. 31, 2015	Feb. 16, 2016	Jun. 30, 2016	Jun. 30, 2015	Feb. 29, 2016
Series A Warrant [Member]
Share Price	$ 13.60		$ 2.93
Fair Value Assumptions, Expected Volatility Rate	72.00%		99.00%
Fair Value Assumptions, Expected Term	5 years 182 days		4 years 255 days
Fair Value Inputs, Discount Rate	1.54%		1.01%
Fair Value Assumptions, Expected Dividend Rate	0.00%		0.00%
Exercise price (in dollars per share)	$ 13.60		$ 8
Series B Warrant [Member]
Share Price	$ 13.60	$ 4
Fair Value Assumptions, Expected Volatility Rate	62.00%	137.00%
Fair Value Assumptions, Expected Term	1 year 182 days	1 year
Fair Value Inputs, Discount Rate	0.57%	0.50%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Exercise price (in dollars per share)	$ 13.60	$ 13.60
Share Price					$ 4
Fair Value Assumptions, Expected Volatility Rate			80.00%	75.00%
Fair Value Assumptions, Expected Term			5 years	5 years
Fair Value Assumptions, Expected Dividend Rate			0.00%	0.00%

Note 6 - Derivative Obligation

Note 6 - Derivative Obligation Fair Value Hierarchy (Details) - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Inputs, Level 1 [Member]
Derivative obligation
Fair Value, Inputs, Level 2 [Member]
Derivative obligation
Fair Value, Inputs, Level 3 [Member]
Derivative obligation	670,000
Derivative obligation	$ 670,000	$ 0

Note 6 - Change in Fair Value o

Note 6 - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Balance	$ 0
Addition of derivative obligation at fair value on date of issuance	4,282,000
Reclassification of derivative obligation for exercised warrants	(58,000)
Extinguishment of derivative obligation	(159,000)
Change in fair value of derivative obligation	(3,395,000)
Balance	$ 670,000	$ 0

Note 7 - Commitments and Cont44

Note 7 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2015
Minimum [Member]
Payment Terms, Severance Compensation	1 year
Period Of Warranty On Products	1 year
Maximum [Member]
Payment Terms, Severance Compensation	2 years
Period Of Warranty On Products Maximum	2 years
Two Key Executives [Member]
Potential Severance Costs	$ 1,147
Resigned President [Member] | Employee Severance [Member]
Restructuring and Related Cost, Expected Cost Remaining	$ 265
Resigned President [Member]
Payment Terms, Severance Compensation	1 year 180 days
Operating Leases, Rent Expense, Net	$ 657	$ 652
Short Term Investment Minimum			$ 2,000

Note 7 - Future Minimum Lease P

Note 7 - Future Minimum Lease Payments for Non-Cancelable Operating Lease (Details) $ in Thousands	Jun. 30, 2016USD ($)
2,017	$ 428
2,018	305
2,019	260
Total	$ 993

Note 7 - Changes in Product Lia

Note 7 - Changes in Product Liability Included in Accrued Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Beginning balance	$ 627	$ 498
Warranties issued during the period	97	258
Settlements made during the period	(287)	(168)
Changes in liability for pre-existing warranties during the period	129	39
Ending balance	$ 566	$ 627

Note 8 - Stockholders' Equity47

Note 8 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 26, 2016	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jul. 07, 2016
Subsequent Event [Member] | The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						325,000
Subsequent Event [Member] | Short Term Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						104,000
Share-based Compensation Arrangement by Share-based Payment Award, Aggregate Amount of Issuable Cash Award						$ 276
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	93,002
Share-based Compensation Arrangement by Share-based Payment Award, Amount of Cash Award Issued in Period	$ 266
Plan 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				25,000
Options Prices In Terms Of Fair Market Value				100.00%
Options Expiry Period				10 years
Common Stock, Capital Shares Reserved for Future Issuance				3,209
2006 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				392,320
Common Stock, Capital Shares Reserved for Future Issuance				177,189
Shares Authorized To Be Issued In Terms Of Outstanding Shares				6.00%
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		50,000
Chief Executive Officer [Member] | Seven Year Option [Member] | Vesting in Equal Monthly Installments [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Chief Executive Officer [Member] | Seven Year Option [Member]
Period of Option		7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%
Chief Executive Officer [Member]
Number of Shares to be Acquired		50,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number					8,334
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 9.64
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options				$ 212
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 354	$ 678
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				10,000	54,850
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number					3,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				180 days
Shares Paid for Tax Withholding for Share Based Compensation				1,300	6,098
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options				$ 375
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense			$ 158
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				0	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 5.75	$ 12.40

Note 8 - Warrant Activity (Deta

Note 8 - Warrant Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Beginning balance (in shares)	252,620	255,671
Beginning balance (in dollars per share)	$ 44.18	$ 44.18
Warrants granted (in shares)	5,238,971
Warrants granted (in dollars per share)	$ 9.83
Warrants exercised (cashless) (in shares)	(51,712)
Warrants exercised (cashless) (in dollars per share)	$ 13.60
Warrants expired/canceled (in shares)	(611,156)	(3,051)
Warrants expired/canceled (in dollars per share)	$ 17.21	$ 43
Outstanding at June 30 (in shares)	4,828,723	252,620
Outstanding at June 30 (in dollars per share)	$ 9.37	$ 44.18
Exercisable at June 30 (in shares)	600,782	252,620
Exercisable at June 30 (in dollars per share)	$ 19.02	$ 44.18

Note 8 - Option Activity For St

Note 8 - Option Activity For Stock Option Plans (Details) - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Employee Stock Option [Member]
Outstanding at, (in shares)	147,609
Outstanding at, (in dollars per share)	$ 25.51
Granted (in shares)	55,875
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 9.64
Forfeited/cancelled (in shares)	(93,855)
Forfeited/cancelled (in dollars per share)	$ 27.02
Expired (in shares)	(5,251)
Expired (in dollars per share)	$ 41.47
Outstanding at, (in shares)	104,378	147,609
Outstanding at, (in dollars per share)	$ 14.85	$ 25.51
Outstanding at,	5 years 292 days
Vested and Expected to Vest at June 30, 2016 (in shares)	91,810
Vested and Expected to Vest at June 30, 2016 (in dollars per share)	$ 15.34
Vested and Expected to Vest at June 30, 2016	5 years 255 days
Exercisable at June 30, 2016 (in shares)	61,271
Exercisable at June 30, 2016 (in dollars per share)	$ 16.15
Exercisable at June 30, 2016	5 years 182 days
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.75	$ 12.40

Note 8 - Non-vested Stock Optio

Note 8 - Non-vested Stock Options Activity (Details) - Non-vested Stock Options [Member]	12 Months Ended
	Jun. 30, 2016$ / sharesshares
Outstanding at, (in shares) | shares	89,198
Outstanding at June 30, 2015 (in dollars per share) | $ / shares	$ 13.07
Granted (in shares) | shares	55,875
Granted (in dollars per share) | $ / shares	$ 5.75
Vested (in shares) | shares	(53,496)
Vested (in dollars per share) | $ / shares	$ 9.79
Forfeited/cancelled (in shares) | shares	(48,470)
Forfeited (in dollars per share) | $ / shares	$ 13.35
Outstanding at, (in shares) | shares	43,107
Outstanding at June 30, 2016 (in dollars per share) | $ / shares	$ 7.66

Note 8 - Fair Value of Stock Op

Note 8 - Fair Value of Stock Options Granted (Details)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Fair Value Assumptions, Expected Term	5 years	5 years
Risk-free interest rate	1.50%	1.50%
Fair Value Assumptions, Expected Volatility Rate	80.00%	75.00%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%

Note 8 - Restricted Stock Activ

Note 8 - Restricted Stock Activity Granted to Employees (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Balance, Number of Shares, (in shares)	72,589	40,190
Balance, Weighted Average Grant Date Fair Value, (in dollars per share)	$ 22.40	$ 38
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	10,000	54,850
Granted,. Weighted Average Grant Date Fair Value (in dollars per share)	$ 2.98	$ 16.60
Vested, Number of Shares (in shares)	(6,120)	(18,828)
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	$ 28.94	$ 36.40
Forfeited, Number of Shares (in shares)	(12,903)	(3,623)
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	$ 41.15	$ 35.40
Outstanding, Number of Shares, (in shares)	63,566	72,589
Outstanding, Weighted Average Grant Date Fair Value, (in dollars per share)	$ 14.96	$ 22.40

Note 9 - Concentrations (Detail

Note 9 - Concentrations (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)
Distributor 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	28.00%	28.00%
Distributor 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	23.00%	15.00%
Distributor 1 [Member]
Accounts Receivable, Net, Current	$ 901	$ 1,423
Revenue, Net	$ 2,797	$ 2,358
Customer 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	19.00%	12.00%
Customer 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	21.00%	16.00%
Customer 1 [Member]
Accounts Receivable, Net, Current	$ 620	$ 615
Revenue, Net	$ 2,475	$ 2,549
Distributor 2 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	10.00%	10.00%
Distributor 2 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage		14.00%
Distributor 2 [Member]
Accounts Receivable, Net, Current	$ 320	$ 520
Revenue, Net		$ 2,303
Distributor 3 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage		14.00%
Distributor 3 [Member]
Accounts Receivable, Net, Current		$ 697
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 1 [Member]
Concentration Risk, Percentage	65.00%	45.00%
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 2 [Member]
Concentration Risk, Percentage	21.00%	17.00%
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 3 [Member]
Concentration Risk, Percentage		13.00%
Accounts Receivable, Net, Current	$ 3,169	$ 5,133
Revenue, Net	$ 11,929	$ 16,042
Number of Suppliers	2	3

Note 9 - Revenues by Product Pl

Note 9 - Revenues by Product Platform (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Product Concentration Risk [Member] | AXP [Member]
Revenue, Net	$ 6,932	$ 6,612
Product Concentration Risk [Member] | BioArchive [Member]
Revenue, Net	2,465	4,241
Product Concentration Risk [Member] | Manual Disposables [Member]
Revenue, Net	1,507	1,810
Product Concentration Risk [Member] | Bone Marrow [Member]
Revenue, Net	459	2,621
Product Concentration Risk [Member] | Other Segments [Member]
Revenue, Net	566	758
Revenue, Net	$ 11,929	$ 16,042

Note 9 - Sales to Customers (De

Note 9 - Sales to Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Geographic Concentration Risk [Member] | UNITED STATES
Revenue, Net	$ 5,122	$ 8,428
Geographic Concentration Risk [Member] | CHINA
Revenue, Net	2,797	2,500
Geographic Concentration Risk [Member] | Asia - Other [Member]
Revenue, Net	1,955	1,955
Geographic Concentration Risk [Member] | Europe [Member]
Revenue, Net	1,343	2,147
Geographic Concentration Risk [Member] | All Other Countries [Member]
Revenue, Net	712	1,012
Revenue, Net	$ 11,929	$ 16,042

Note 9 - Summary of Net Equipme

Note 9 - Summary of Net Equipment by Geographic Area (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Geographic Concentration Risk [Member] | UNITED STATES
Property, Plant, and Equipment, Net	$ 2,030	$ 1,409
Geographic Concentration Risk [Member] | COSTA RICA
Property, Plant, and Equipment, Net	367	594
Geographic Concentration Risk [Member] | INDIA
Property, Plant, and Equipment, Net	279	296
Geographic Concentration Risk [Member] | CHINA
Property, Plant, and Equipment, Net	225	524
Geographic Concentration Risk [Member] | All Other Countries [Member]
Property, Plant, and Equipment, Net	61	114
Property, Plant, and Equipment, Net	$ 2,962	$ 2,937

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Domestic Tax Authority [Member]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$ 17,789,000	$ 14,041,000
Operating Loss Carryforwards	110,819,000
Tax Credit Carryforward, Amount	1,418,000
Foreign Tax Authority [Member]
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	799,000	811,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards		$ 45,284,000
Tax Credit Carryforward, Amount	1,437,000
Income Tax Benefit	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Deferred Income Tax Expense (Benefit)	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	3,484,000
Tax Benefits Related To Stock Options Included In Valuation Allowance	$ 219,000

Note 10 - Reconciliation of Fed

Note 10 - Reconciliation of Federal Income Tax Attributable to Operations to Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Statutory federal income tax benefit	$ (6,300)	$ (5,046)
Unbenefited net operating losses and credits	3,391	5,091
Disallowed financing costs	2,607
State and local taxes	69	(33)
Other	233	(12)
Total income tax expense

Note 10 - Components of Company

Note 10 - Components of Company's Deferred Tax Assets and Liabilities for Federal and State Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Jun. 30, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 41,023	$ 38,317
Income tax credit carryforwards	2,367	2,143
Stock compensation	874	916
Other	1,345	1,479
Valuation allowance	(45,892)	(42,408)
Total deferred taxes	(283)	447
Deferred tax liabilities
Depreciation and amortization	(7,358)	(8,088)
Net deferred taxes and liabilities	$ (7,641)	$ (7,641)

Note 11 - Employee Retirement60

Note 11 - Employee Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Defined Benefit Plan, Contributions by Employer	$ 0	$ 0

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 22, 2016	Aug. 03, 2016	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2015
Subsequent Event [Member] | Three-Year Debentures [Member]
Debt Conversion, Original Debt Principal, Amount	$ 12,500
Debt Conversion, Original Debt Interest, Amount	$ 8,250
Debt Conversion, Converted Instrument, Shares Issued	6,102,941
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues		600,000
Shares Issued, Price Per Share		$ 4.10
Proceeds from Issuance of Common Stock		$ 2,200
Debt Conversion, Converted Instrument, Shares Issued	6,102,941
Stock Issued During Period, Shares, New Issues			735,294
Proceeds from Issuance of Common Stock				$ 2,463